Liquid biopsy in lymphomas: a potential tool for refining diagnosis and disease monitoring

Riccardo Moia, Chiara Favini, Silvia Rasi, Clara Deambrogi, Valentina Ferri, Mattia Schipani, Sruthi Sagiraju, Abdurraouf Mokhtar Mahmoud, Ahad Ahmed Kodipad, Ramesh Adhinaveni, Andrea Patriarca, Luca Nassi, Gianluca Gaidano

Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont and Ospedale Maggiore della Carità, Novara 28100, Italy.

Correspondence to: Prof. Gianluca Gaidano, Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont and Ospedale Maggiore della Carità, Novara 28100, Italy. E-mail: gianluca.gaidano@uniupo.it

How to cite this article: Moia R, Favini C, Rasi S, Deambrogi C, Ferri V, Schipani M, Sagiraju S, Mokhtar Mahmoud A, Kodipad AA, Adhinaveni R, Patriarca A, Nassi L, Gaidano G. Liquid biopsy in lymphomas: a potential tool for refining diagnosis and disease monitoring. J Cancer Metastasis Treat 2019;5:67. http:/dx.doi.org/10.20517/2394-4722.2019.020

Received: 23 Jul 2019  First Decision: 21 Aug 2019  Revised: 28 Aug 2019  Accepted: 2 Sep 2019  Published: 4 Sep 2019

Science Editor: Ciro Isidoro  Copy Editor: Cai-Hong Wang  Production Editor: Jing Yu

Abstract

Liquid biopsy consists in a simple blood sampling that allows to analyze cell free DNA (cfDNA), containing specific genomic clues released by the tumor into the bloodstream. In this review, we shall focus on the analysis of cfDNA in lymphoma and, in particular, on its application in the genotyping and monitoring of two common types of B-cell lymphoma, i.e., diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL). From a diagnostic standpoint and based upon the current international guidelines, lymphoma diagnosis has so far relied on the analysis of the tissue biopsy. From a molecular viewpoint, though, the tissue biopsy does not reflect the entire molecular heterogeneity of lymphomas. In fact, in an individual patient, lymph nodes at different anatomical sites, as well as different areas of the same lymph node, may show different genetic profiles. Consequently, molecular analysis of genomic DNA extracted from a single lymph node biopsy may not recapitulate the whole mutational landscape of the disease. Liquid biopsy may overcome this hurdle, since cfDNA is released by all tumoral cells and can reveal the entire molecular complexity of lymphomas. From a translational perspective, liquid biopsy may also be used to evaluate clonal evolution, response to therapy and minimal residual disease. Consistently, in DLBCL as well in cHL, the drop of the mutational burden during the treatment course provides complementary information to conventional imaging techniques. The integration of liquid biopsy with imaging techniques may prove useful for a better prediction of patients’ outcome and for a better treatment tailoring.

Keywords: Liquid biopsy, lymphoma, precision medicine
GENERAL CONCEPT ON CIRCULATING CELL FREE DNA

Liquid biopsy consists in a simple and easy sampling of peripheral blood, that can be subjected to the molecular analysis of specific genomic clues released by the tumor\(^{[1,2]}\). Because circulating tumor cells are very rare or absent in many types of lymphomas, liquid biopsy approaches have been focused on circulating tumoral DNA (ctDNA) released by lymphoma cells into the bloodstream\(^{[3-5]}\). However, the ctDNA represents only a fraction of the total amount of cell free DNA (cfDNA), that is derived also from healthy cells. The cfDNA circulates in plasma at a low concentration as double-stranded DNA fragments with a dimension < 200 base pairs\(^{[6]}\). In individuals without malignancies, plasma cfDNA derives mainly from the apoptosis of normal hematopoietic cells. cfDNA levels may also rise in para-physiological conditions, such as trauma, burns or high exercise. In healthy subjects, the cfDNA concentration ranges between 1 and 10 ng/mL and can reach 30ng/mL in lymphoma patients\(^{[7]}\).

CFDNA ISOLATION

It is possible to selectively isolate cfDNA from plasma in order to proceed with subsequent molecular analysis\(^{[8]}\). To isolate cfDNA, a few very important technical precautions need to be observed in order to avoid white blood cell lysis that may contaminate the cfDNA with genomic DNA (gDNA)\(^{[9]}\). If using standard collecting tubes containing ethylenediaminetetraacetic-acid (EDTA) as anticoagulant, plasma extraction is recommended within 3 h from the collection of peripheral blood\(^{[9]}\). EDTA tubes, however, are not able to preserve the integrity of cfDNA and are not able to prevent the lysis of nucleated cells for more than 3 h. Therefore, in order to allow the shipment of biological material, specific tubes, namely cfDNA BCT Streck tubes (Streck), can stabilize cfDNA and can prevent the contamination by gDNA from white blood cells for up to 14 days at a temperature between 6 and 37 °C\(^{[10]}\). After collection, plasma is separated from the corpuscular blood by centrifugation of blood samples at 800 rpm at 4 °C for 10 min. A second centrifugation at 13,000 rpm at 4 °C for 10 min allows to pellet and remove any remaining cells. Plasma samples are then stored in 1 mL aliquots at -80 °C until cfDNA extraction\(^{[8]}\).

cfDNA can be selectively extracted using two different methods. The first method, named QIAamp Circulating Nucleic Acid (Qiagen), relies on the use of ion-exchange resins that bind the plasma cfDNA\(^{[11]}\). The second approach relies on an automatic method that utilizes the Maxwell RSC Instrument coupled with Maxwell RSC ccfDNA Plasma Kit (Promega). This method consists in an automated nucleic acid purification platform that processes up to 16 samples simultaneously and allows to obtain high quality cfDNA starting from 1 mL of plasma\(^{[12]}\). After extraction, cfDNA is usually quantified by a fluorometric assay. Approximately 30-40 ng of cfDNA are needed for subsequent molecular analysis\(^{[8]}\).

CAPP-SEQ ANALYSIS AS FOR DEFINING THE LYMPHOMA GENOTYPE ON CFDNA

Since lymphoid malignancies harbor a unique molecular marker, namely the immunoglobulin (Ig) gene rearrangement, the identification of presence of this biomarker in the cfDNA may be used to track minimal residual disease (MRD) during the course of treatment. Once the Ig gene rearrangement has been identified on the lymph node biopsy, it is possible to evaluate the amount of this rearrangement in the cfDNA using Next-Generation-Sequencing (NGS) or polymerase chain reaction based methods\(^{[13,14]}\). Pivotal studies have shown that the proportion of cfDNA carrying the lymphoma-specific Ig rearrangement decreases rapidly in patients who respond to therapy and tends to remain negative in those who maintain the response\(^{[13,14]}\). Conversely, the Ig rearrangement remains high in patients who do not respond to treatment\(^{[13,14]}\). As expected, these patients experience both a worse progression-free survival and a worse overall survival compared to patients with undetectable Ig gene rearrangement\(^{[13,14]}\). This method is very effective in monitoring MRD but has some pitfalls. First, this method does not work in a biopsy free manner since it requires, at the time of diagnosis, the identification of the individual patient’s specific Ig
rearrangement on the lymph node tissue biopsy. Once the patient’s unique Ig rearrangement has been identified on the tissue biopsy, it is then possible to track it on the liquid biopsy to evaluate MRD. Second, this method does not allow a comprehensive disease genotyping on the liquid biopsy.

To overcome these limits, the use of Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) has been established as a reliable tool to genotype cancer patients. This molecular strategy utilizes disease specific probes that selectively capture a set of exonic and intronic regions known to be recurrently affected in a particular cancer type. The selected targets are then amplified and sequenced by NGS allowing the detection of the specific tumor mutational profile of a patient. This method, linked to a stringent bioinformatic analysis, allows to detect mutations in cfDNA with a high sensitivity, identifying mutations with allelic frequency as low as 0.02%. In addition, CAPP-Seq allows the identification of single nucleotide variants, as well as insertion/deletions, copy number alterations and rearrangements, thus covering a large variety of genomic alterations of human cancers.

APPLICATION OF LIQUID BIOPSY IN LYMPHOMA

Lymph node biopsy is the gold standard for the diagnosis of lymphoma, but genetic lesions identified in the tissue biopsy may not reflect the entire molecular complexity of every single patient with lymphoma. Consistently, in an individual patient, lymph nodes at different anatomical sites, as well as different areas of the same lymph node, may show different genetic profiles. However, outside of clinical studies aimed at investigating the clonal heterogeneity of lymphomas, multiple biopsies are not routinely performed in lymphoma patients for both practical and ethical concerns. On these grounds, once a diagnosis of lymphoma is performed on a tissue biopsy, liquid biopsy may be used to explore the entire mutational landscape of lymphoma, since this approach has the potential to collect the tumor cfDNA deriving from most, or potentially all, of the different sites of tumor involvement in the body. In particular, a liquid biopsy CAPP-Seq approach may be used to: (1) genotype lymphoma patients; and to (2) evaluate treatment response.

LIQUID BIOPSY AS A TOOL FOR GENOTYPING LYMPHOMA PATIENTS

In DLBCL, liquid biopsy allows to identify at least one somatic non-synonymous mutation per patient in over 70% of cases. The mutational profile identified by liquid biopsy reflects that revealed by DLBCL genomic studies performed on the lymph node biopsies. More precisely, the most common genetic lesions found by liquid biopsy reflect those detected on the tissue biopsy, and comprise alterations of KMT2D, followed by TP53, CREBBP, and PIM1. In addition, EZH2 and BCL2 mutations, as expected, are more frequently found in germinal center (GC) DLBCL, whereas TNFAIP3 and PIM1 mutations are more frequent in non-GC DLBCL. In addition, by comparing the mutations identified in cfDNA with those identified in gDNA extracted from the tissue biopsy, cfDNA appears to be representative of most of the mutations that occur in > 20% of the alleles of the tumor biopsy, with a sensitivity > 90% and a specificity of ∼100%. Furthermore, a fraction of mutations has been found exclusively in cfDNA, conceivably because, due to spatial tumor heterogeneity, they are restricted to clones that are anatomically distant from the biopsy site.

Regarding cHL, the rarity of neoplastic Hodgkin and Reed-Sternberg (HRS) cells in the biopsy has limited the assessments of the genetic landscape of the disease. In this context, liquid biopsy may be a reliable tool to overcome this limit. Analogous to DLBCL, it has been demonstrated that cfDNA analysis in cHL mirrors the genetics of HRS cells micro-dissected from the tissue biopsy. Consistently, most of cHL mutations are identified in the tissue biopsy as well as in the cfDNA and some more mutations are identified only in cfDNA, conceivably because they are derived from different anatomical sites. Genotyping of cHL on the liquid biopsy has allowed to refine the current knowledge of cHL genetics.
STAT6, not previously reported in exome sequencing studies of this lymphoma, has been identified as the most frequently mutated gene in cHL, underlying the importance of cytokine signaling in the biology of this tumor\textsuperscript{[23]}\textsuperscript{45}. Also, liquid biopsy has documented that different histologic subtypes of cHL are biologically distinct. STAT6 and TNFAIP3 mutations are enriched in nodular sclerosis cHL compared with mixed cellularity cases. Also, NF-κB, PI3K-AKT, cytokine and NOTCH signaling pathways, are frequently deregulated by gene mutations, and might be relevant for the biology of the disease and for the identification of potential therapeutic targets\textsuperscript{[23]}\textsuperscript{45}.

LIQUID BIOPSY AS A TOOL TO EVALUATE TREATMENT RESPONSE

In cHL, imaging techniques, such as interim positron emission tomography/computer tomography (PET/CT) scan after 2 cycles of chemotherapy, provide a powerful tool to predict cHL outcome before completion of chemotherapy\textsuperscript{[24-26]}. However, interim PET/CT results are inconsistent with the final outcome in 20% to 30% of patients\textsuperscript{[24-26]}. This lack of specificity and/or sensibility may be corrected, at least in part, by monitoring ctDNA concentration during the course of treatment. A recent study prospectively analyzed ctDNA during treatment in a cohort of 24 cHL patients homogenously treated with adriamycin, bleomycin, vinblastine, dacarbazine (ABVD)\textsuperscript{[23]}\textsuperscript{45}. The study showed that ctDNA analysis may complement interim PET/CT in predicting patients’ outcome\textsuperscript{[23]}. More precisely, patients achieving a complete response had a larger drop in the ctDNA load after 2 ABVD courses compared to refractory patients. Also, a 2-log drop
in ctDNA after 2 chemotherapy courses sorted out as the best cutoff to predict progression. Indeed, cured patients who were inconsistently judged as interim PET/CT-positive achieved more than a 2-log drop in ctDNA, whereas relapsing patients who were inconsistently judged as interim PET/CT negative achieved less than a 2-log drop in ctDNA[23].

Similarly, ctDNA analysis by CAPP-Seq methodology also allows to evaluate treatment response in DLBCL patients. ctDNA has been analyzed at baseline and during the course of treatment in a multicenter cohort of 217 patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) or R-CHOP-like chemo-immunotherapy[21]. Two different thresholds have been identified to optimally predict patients’ outcome, namely early molecular response (EMR) and major molecular response (MMR). These thresholds, including a 2-log drop in ctDNA after one cycle (EMR) and a 2.5-log drop after two cycles (MMR), predict event-free survival after front-line therapy in the training cohort and in two validation sets[21]. Interestingly, the prognostic value of molecular response maintained an independent association with an increased risk of progression and death also in multivariate analyses[21].

Recently, a new prediction tool for DLBCL patients, namely Continuous Individualized Risk Index (CIRI), has been documented to dynamically determine outcome probabilities for individual patients utilizing risk predictors acquired over time, including clinical, radiological and molecular markers identified with a liquid biopsy approach[27].
CONCLUSIONS AND FUTURE PERSPECTIVES

In conclusion, liquid biopsy is a non-invasive method that may be used in lymphomas to achieve several objectives: (1) better characterize the biology and pathogenesis of the lymphoma through the analysis of biological markers that reflect the entire molecular heterogeneity of the disease in its different anatomical sites; (2) identify new prognostic and predictive markers; and (3) prospectively evaluate the dynamics of ctDNA during treatment in order to predict the probability of response to treatment in a more sensitive and specific manner and, if necessary, the need for an early switch to a more efficacious treatment. In order to validate these initial results, several ongoing clinical trials aim at assessing whether cfDNA genotyping can improve outcome prediction in lymphoid malignancies and whether it might identify mutations predisposing to treatment resistance (NCT03280394, NCT02883517, NCT03702309).

In addition to the previously mentioned application of liquid biopsy in lymphoma, preliminary evidence also suggests that cfDNA analysis might reflect the methylation profile identified in the tissue biopsy. More precisely, global hypomethylation of the genome, as well as aberrant methylation of specific regions of interest detected on the liquid biopsy, namely DAPK1 promoter hypermethylation, might represent potential prognostic biomarkers in lymphomas.

The liquid biopsy of lymphoma, as described in this review, aims at analysing mutations of somatic origin, and therefore does not pose major ethical issues beyond the conventional ethical requirements. If the patient plasma is stored in a biobank for subsequent analysis, the conventional guidelines for biobanking should be followed.

DECLARATIONS

Authors’ contributions
Writing, reviewing and editing the manuscript: Moia R, Favini C, Rasi S, Deambrogi C, Ferri V, Schipani M, Sagiraju S, Mokhtar Mahmoud A, Kodipad AA, Adhinaveni R, Patriarca A, Nassi L, Gaidano G

Availability of data and materials
Not applicable.

Financial support and sponsorship
Work by the authors described in this review has been supported by Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies, (5 ’ 1000 No. 21198), Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy; Progetto Ricerca Finalizzata RF-2011-02349712, Ministero della Salute, Rome, Italy; PRIN 2015ZMRFEA_004, MIUR, Rome, Italy; and AGING Project - Department of Excellence - DIMET, Università del Piemonte Orientale, Novara, Italy.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.
REFERENCES

1. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 2018;36:1631-41.

2. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 2017;14:531-48.

3. Arzuaga-Mendez J, Prieto-Fernández E, Lopez-Lopez E, Martín-Guerrero I, García-Ruiz JC, et al. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: a systematic review. Crit Rev Oncol Hematol 2019;139:7-15.

4. Melani C, Wilson WH, Roschewski M. Liquid biopsy in non-Hodgkin’s lymphoma. Hematol Oncol 2019;37 Suppl 1:70-4.

5. Crombie J, Armand P. The emerging role of liquid biopsies in lymphoproliferative disorders. Curr Hematol Malig Rep 2019;14:11-21.

6. Wan JCM, Massie C, García-Corbacho J, Mouliere F, Brenton JD, et al. Liquid biopsies come of age: towards implementation of circulating tumor DNA. Nat Rev Cancer 2017;17:223-38.

7. Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA Comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 2016;164:57-68.

8. Rossi D, Condoluci A, Spina V, Gaidano G. Methods for measuring ctDNA in lymphomas. Methods Mol Biol 2019;1881:253-65.

9. El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 2013;424:222-30.

10. Streck (2014) Cell-free DNA BCT: instructions for use. Omaha, NE. Available from: https://www.streck.com/news/2016-09-19-Streck-

11. Qiagen (2013) QIAamp® circulating nucleic acid handbook. 3rd ed. Available from: https://www.qiagen.com/us/resources/download.aspx?id=10c4b31ab-f4fb-425f-99bf-10ab9538e061&lang=4en. [Last accessed on 2 Sep 2019]

12. Pérez-Barrios C, Nieto-Alcolado I, Torrente M, Jiménez-Sánchez C, Calvo V, et al. Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing. Transl Lung Cancer Res 2016;5:665-72.

13. Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 2015;125:3679-87.

14. Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 2015;16:541-9.

15. Rossi D, Spina V, Bruscaggin A, Gaidano G. Liquid biopsy in lymphoma. Haematologica 2019;104:648-52.

16. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548-54.

17. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, et al. Diffuse large B-cell lymphoma: ESMO Clinical Practice Guidelines. Ann Oncol 2015;26:v116-25.

18. Eichenauer DA, Alemán BMP, André M, Federico M, Hutchings M, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv9-29.

19. Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, et al. Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Leukemia 2019;32:1261-5.

20. Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood 2017;129:1947-57.

21. Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol 2018;36:2845-54.

22. Pasqualucci L, Dalla-Favera R. The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol 2015;52:67-76.

23. Spina V, Bruscaggin A, Cuaceno A, Martini M, Di Trani M, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 2018;131:2413-25.

24. Gallamini A, Rigacci L, Merli F, Nasti L, Bosi A, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica 2006;91:475-81.

25. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-52.

26. Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis. Br J Haematol 2015;170:356-66.

27. Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, et al. Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction. Cell 2019;178:699-713.e19.

28. ClinicalTrials.gov. National Library of Medicine (U.S.). Liquid Biopsy in Mature B-cell Tumors. Identifier NCT03280394. Available from: https://clinicaltrials.gov/ct2/show/NCT03280394. [Last accessed on 2 Sep 2019]

29. ClinicalTrials.gov. National Library of Medicine (U.S.). Liquid Biopsy in Primary Cutaneous Lymphomas (MATULILA). Identifier NCT02883517. Available from: https://clinicaltrials.gov/ct2/show/NCT02883517. [Last accessed on 2 Sep 2019]

30. ClinicalTrials.gov. National Library of Medicine (U.S.). Liquid Biopsy Evaluation and Repository Development at Princess Margaret (LIBERATE). Identifier NCT03702309. Available from: https://clinicaltrials.gov/ct2/show/NCT03702309. [Last accessed on 2 Sep 2019]
large B cell lymphoma. Am J Hematol 2017;92:689-94.

32. Kristensen LS, Hansen JW, Kristensen SS, Tholstrup D, Harsløf LB, et al. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma. Clin Epigenetics 2016;8:95.

33. Hallmans G, Vaught JB. Best practices for establishing a biobank. Methods Mol Biol 2011;675:241-60.

34. Baker M. Biorepositories: building better biobanks. Nature 2012;486:141-6.